Anand Bhat, MD
Allergy & Immunology · Shreveport, LANPI 1992084750
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 279 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 31 manufacturers reported payments, led by AstraZeneca at 28.1% of the total. 2025 is the largest year on record at $2,594, more than ten times the $158 reported in 2019.
Across 279 payments — averaging $33.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Regeneron Healthcare Solutions, Inc.$2K
- Biocryst US Sales Co., LLC$1K
- GSK$993
- Itamar Medical Inc$386
- Sanofi$378
- plus $2K from 25 others
What the payments were for
- Food & beverage$9,10299%
- Education$1201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 78 | $2,595 |
| Regeneron Healthcare Solutions, Inc. | 51 | $1,501 |
| Biocryst US Sales Co., LLC | 18 | $1,095 |
| GSK | 32 | $993 |
| Itamar Medical Inc | 4 | $386 |
| Sanofi | 15 | $378 |
| Genentech USA, Inc. | 18 | $320 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $236 |
| ARS Pharmaceuticals Operations, Inc. | 6 | $160 |
| Pharming Healthcare, Inc. | 3 | $151 |
| Novartis | 8 | $144 |
| Amgen | 4 | $136 |
| Jazz Pharmaceuticals Inc. | 1 | $127 |
| Ionis Pharmaceuticals, Inc. | 1 | $125 |
| Mylan Specialty L.p. | 1 | $125 |
| CSL Behring | 4 | $119 |
| Alk-abello, Inc | 2 | $97 |
| Aimmune Therapeutics, Inc. | 3 | $72 |
| Kaleo, Inc. | 3 | $72 |
| Harmony Biosciences LLC | 2 | $66 |
| Jubilant Hollisterstier LLC | 2 | $56 |
| Octapharma USA, Inc. | 1 | $43 |
| Blueprint Medicines Corporation | 2 | $38 |
| Inspire Medical Systems, Inc. | 1 | $37 |
| Phadia US Inc. | 2 | $37 |
| Hospira, Inc. | 2 | $30 |
| Incyte Corporation | 1 | $19 |
| Boehringer Ingelheim | 1 | $18 |
| Greer Laboratories, Inc. | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,222 in reported general payments places this provider in the 80th percentile of 62 allergy & immunology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 51 | $191,549 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 54 | $38,105 |
| XolairOmalizumab | 12 | $30,564 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 20 | $12,125 |
| Epinephrine | 12 | $2,616 |
| Ipratropium Bromide | 16 | $707 |
| Azelastine Hcl | 20 | $454 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 16 | $356 |
| Triamcinolone Acetonide | 14 | $106 |
| Prednisone | 35 | $101 |
| Mupirocin | 15 | $101 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $993 | $38,10554 claims |
| AstraZenecaBreztri Aerosphere | $2,595 | $12,12520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 62 allergy & immunology providers in Louisiana.
Other allergy & immunology in Shreveport
- David KaufmanShreveport$678K
- Caroline CapertonShreveport$52K
- Gonzalo Alvarez del RealShreveport$8K
- Lori JohnsonShreveport$5K
- Hannah FucinariShreveport$4K
- Andria CheramieShreveport$3K
- Priyal UpadhyayShreveport$2K
- Steven WhitedShreveport$451
- Reena MehtaNew Orleans$159K
- Kenneth ParisNew Orleans$150K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.